Evidence map›Paper›PMID 37309097›Full record

ArticleAnnals of transplantation2023

Incidence of Thromboembolic Complications Following Kidney Transplantation with Short and Extended Aspirin Prophylaxis: A Retrospective Single-Center Study.

Angus H Pegler, Katharine Hegerty, Ryan P Gately, Carmel M Hawley, David W Johnson, Yeoungjee Cho, Dev K Jegatheesan, Andrew B McCann, Michelle E Harfield, Nicole M Isbel

Open access · hybridAbstract read
In one paragraph

Article in Annals of transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Management of antithrombotic therapies in kidney transplantation candidates and recipients: an ERBP clinical practice document by the DESCaRTES Working Group of ERA and the EKITA Committee of ESOT.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Angus H PeglerDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.ORCID 0000-0003-3725-8251
Katharine HegertyDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.ORCID 0000-0001-9175-5406
Ryan P GatelyDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Carmel M HawleyDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
David W JohnsonDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.ORCID 0000-0001-5491-3460
Yeoungjee ChoDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Dev K JegatheesanDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Andrew B McCannDepartment of Vascular Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Michelle E HarfieldDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Nicole M IsbelDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Princess Alexandra Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Aspirin prophylaxis has been associated with reduced graft-related thrombosis following kidney transplantation. Aspirin cessation, however, can increase risk of venous thromboembolic complications, including pulmonary thromboembolism and deep venous thrombosis. This single-center, retrospective, pre-post interventional study from Brisbane, Australia, aimed to compare the rate of thrombotic complications in 1208 adult kidney transplant recipients receiving postoperative aspirin for 5 days or >6 weeks. MATERIAL AND METHODS We enrolled1208 kidney transplant recipients who received 100 mg aspirin for 5 days (n=571) or >6 weeks (n=637) postoperatively. The primary outcome was venous thromboembolism (VTE) in the first 6 weeks after transplant, examined by multivariable logistic regression analysis. Secondary outcomes were renal vein/artery thrombosis, 1-month serum creatinine, rejection, myocardial infarction, stroke, blood transfusion, dialysis at day 5 and day 28, and mortality. RESULTS Sixteen (1.3%) patients experienced VTE (5-day n=8, 1.4%; >6-week n=8, 1.3%; P=0.8). Extended aspirin duration was not independently associated with a reduction in VTE (OR 0.91, 95% CI 0.32-2.57; P=0.9). Graft thrombosis was rare (n=3, 0.25%). Aspirin duration was not associated with cardiovascular events, blood transfusion, graft thrombosis, graft dysfunction, rejection, or mortality. VTE was independently associated with older age (OR 1.09, 95% CI 1.04-1.16; P=0.002), smoking (OR 3.59, 95% CI 1.20-13.2; P=0.032), younger donor age (OR 0.96, 95% CI 0.93-1.00; P=0.036), and thymoglobulin use (OR 10.5, 95% CI 3.09-32.1; P≥0.001). CONCLUSIONS Extended-duration aspirin use did not significantly reduce the incidence of VTE in the first 6 weeks following kidney transplantation. An association was identified between anti-human thymocyte immunoglobulin and VTE, which requires further assessment.

Indexed as

Kidney TransplantationVenous ThromboembolismAdultAspirinHumansIncidenceRetrospective StudiesAspirin

Identifiers

PMID37309097
PMCPMC10276531
OpenAlexW4376617269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.